Integrating innovative technologies for genotyping and phenotyping in stratified medicine
Lead Research Organisation:
University of Birmingham
Department Name: Immunity and Infection
Abstract
The mechanisms associated with how a disease develops and progresses, or response to a treatment, are not identical but are dependent on the human subject. The strategy defined as stratified medicine is based on grouping patients with distinct mechanisms of disease, or particular responses to treatments in order to identify and apply treatments that are effective for particular groups of patients. This provides the opportunity to rapidly define or alter patient management and treatments early, providing a maximum benefit to the patient. To achieve this, it is necessary to combine data on the chemical composition of cells and biofluids like urine, with data related to age, gender and other characteristics to provide information on how to diagnose a disease, to identify the correct treatment rapidly, and to monitor patients based on risk of relapse. The aim is this strategy is to deliver a system of monitoring and treatment which is tailored towards the individual patient.
We are proposing to build upon the world-leading clinical and research environment within Birmingham by creating a West Midlands Stratified Medicine Innovation & Translation Facility through major infrastructure investment, aligned to an ambitious research programme which will enhance our mechanistic knowledge as well as diagnostic and clinical capabilities. Research will particularly focus on immune-mediated inflammatory diseases (e.g. arthritis and liver disease) and blood cancers (e.g. leukaemia), which are increasing in prevalence in the UK, partly as a consequence of an aging population. Our interdisciplinary research programme will focus on the molecular study and characterisation of different cell types within each disease and the associated molecular changes in the patient. It will develop and test the integration of multiple diagnostic strands including methods called mass cytometry, metabolic phenotyping and single-cell genomics and functional genomics. We will obtain new insight into the mechanisms of how diseases develop and progress, and their responsiveness to treatment, with the aim to drive innovative discoveries into clinical practice through the establishment of stratified diagnostics and targeted therapies. This will not only build on local investments such as the £24m Institute for Translational Medicine (co-funded by government, along with our NHS partners University Hospitals Birmingham) and the new £4.1m Centre for Computational Biology, but also concurrent national investments in new technology such as CyTOF cell sorting and the recent MRC-NIHR National Phenome Centre, all of whom we are collaborating with to enable a step-change in national capabilities in stratified medicine research.
We are proposing to build upon the world-leading clinical and research environment within Birmingham by creating a West Midlands Stratified Medicine Innovation & Translation Facility through major infrastructure investment, aligned to an ambitious research programme which will enhance our mechanistic knowledge as well as diagnostic and clinical capabilities. Research will particularly focus on immune-mediated inflammatory diseases (e.g. arthritis and liver disease) and blood cancers (e.g. leukaemia), which are increasing in prevalence in the UK, partly as a consequence of an aging population. Our interdisciplinary research programme will focus on the molecular study and characterisation of different cell types within each disease and the associated molecular changes in the patient. It will develop and test the integration of multiple diagnostic strands including methods called mass cytometry, metabolic phenotyping and single-cell genomics and functional genomics. We will obtain new insight into the mechanisms of how diseases develop and progress, and their responsiveness to treatment, with the aim to drive innovative discoveries into clinical practice through the establishment of stratified diagnostics and targeted therapies. This will not only build on local investments such as the £24m Institute for Translational Medicine (co-funded by government, along with our NHS partners University Hospitals Birmingham) and the new £4.1m Centre for Computational Biology, but also concurrent national investments in new technology such as CyTOF cell sorting and the recent MRC-NIHR National Phenome Centre, all of whom we are collaborating with to enable a step-change in national capabilities in stratified medicine research.
Technical Summary
Stratified medicine is applied to group patients based on specific disease phenotype, mechanism of onset or progression and response to treatment; these mechanisms are specific to individual patients and means a personalised approach to management throughout a patient journey is required to maximise patient survival and minimise healthcare costs. To develop novel stratified medicine approaches, we will integrate multiple clinical and molecular datasets for diagnosis and management of disease, with the aim of delivering a system of monitoring and treatment which is tailored towards the individual patient. These type of data integration must (i) inform research into disease causation and development, (ii) contribute to patient management and (iii) provide insights towards novel therapeutics. We are proposing to build upon the unique integrated clinical and research setting within Birmingham by creating a West Midlands Stratified Medicine Innovation & Translation Facility through major infrastructure investment, aligned to an ambitious research programme which will enhance our mechanistic knowledge as well as diagnostic and clinical capabilities. Research will particularly focus on immune-mediated inflammatory diseases and blood cancers, which are disciplines of great local strength. This will not only build on local investments such as the £24m Institute for Translational Medicine (co-funded by government, along with our NHS partners University Hospitals Birmingham) and the new £4.1m Centre for Computational Biology, but also concurrent national investments in new technology such as CyTOF cell sorting and the recent MRC-NIHR National Phenome Centre, all of whom we are collaborating with to enable a step-change in national capabilities in stratified medicine research.
Planned Impact
Stratified medicine is one of the cornerstones of MRC's ambitions to secure impact from medical research, and we believe that there are four key areas in which this proposal can offer significant value:
The primary area of impact is around HEALTH, building on outstanding clinically-focused programmes of research in Birmingham in blood cancers, chronic inflammatory disease (particularly rheumatology), liver disease and rare disease. Links with clinical services such as the West Midlands Regional Genetics Laboratory and Clinical Immunology Service are crucial to realizing benefit in these areas, as is the integration with extensive existing healthcare data through our collaborators such as University Hospitals Birmingham and Birmingham Children's Hospital through the Birmingham Health Partners strategic alliance. Through our clinical academic teams and our NHS partners we have excellent links to existing patient groups as well as clinicians themselves, and the development of the proposed facility within the new £24m Institute for Translational Medicine offers clear opportunities to continue to develop new collaborations and raise awareness of the potential of new approaches aligned to our three key aims: (i) inform research into disease pathogenesis and responsiveness to treatment, (ii) contribute to patient management, and (iii) provide insights towards novel therapeutics. Public engagement programmes will also be a key factor throughout the project lifecycle, supported both by the University and our BHP collaborators, including direct personal engagement as well as wider media communications in partnership with the funding bodies supporting this proposal.
With respect to ECONOMIC impact, we already have a proven track record in developing new diagnostics into robust routine clinical laboratory practice, commercialising these assays and disseminating them worldwide (thebindingsite.com, serascience.com), and we anticipate significant further commercial opportunities through the research programme outlined here. Development of metabolomic capacity and provision is not only intended to engage with other research areas but also provide a service to industry partners involved in therapeutics, healthcare and nutrition. Note that the proposal already has strong buy-in from industry partners in terms of technology development and implementation, with £4.2m contributed from instrument suppliers (in-kind contributions over the next five years of £2.5m and discounts on instruments of £1.7m).
We will also have major ACADEMIC impacts, where as stated our programme of work will inform research into disease pathogenesis and responsiveness to treatment, building particularly on local excellence in immune-mediated inflammatory diseases and blood cancers. Through our academic conferences as well as our existing national programmes (e.g. NIHR BRU, MRC-ARUK Centre, ARUK Centre, NIHR TRP) we will disseminate our findings, and will continue to engage with the other academic teams applying to the present call for CyTOF instruments to realise added value on a national scale. The establishment of the West Midlands Regional Phenome Centre will also have international impact in the field, providing a lasting infrastructure to support the growing requirements of phenomics in the clinical and population health arena in the UK.
Finally, we will also strive to influence key POLICY impacts, working with our clinical partners as well as organisations such as the West Midlands Academic Health Sciences Network and the funding bodies themselves, particularly in the fields of blood cancer trials and chronic inflammatory disease, to ensure that the discoveries and outputs of our research help to inform policy at a local, national and international level in terms of proactive approaches to patient stratification and treatment.
The primary area of impact is around HEALTH, building on outstanding clinically-focused programmes of research in Birmingham in blood cancers, chronic inflammatory disease (particularly rheumatology), liver disease and rare disease. Links with clinical services such as the West Midlands Regional Genetics Laboratory and Clinical Immunology Service are crucial to realizing benefit in these areas, as is the integration with extensive existing healthcare data through our collaborators such as University Hospitals Birmingham and Birmingham Children's Hospital through the Birmingham Health Partners strategic alliance. Through our clinical academic teams and our NHS partners we have excellent links to existing patient groups as well as clinicians themselves, and the development of the proposed facility within the new £24m Institute for Translational Medicine offers clear opportunities to continue to develop new collaborations and raise awareness of the potential of new approaches aligned to our three key aims: (i) inform research into disease pathogenesis and responsiveness to treatment, (ii) contribute to patient management, and (iii) provide insights towards novel therapeutics. Public engagement programmes will also be a key factor throughout the project lifecycle, supported both by the University and our BHP collaborators, including direct personal engagement as well as wider media communications in partnership with the funding bodies supporting this proposal.
With respect to ECONOMIC impact, we already have a proven track record in developing new diagnostics into robust routine clinical laboratory practice, commercialising these assays and disseminating them worldwide (thebindingsite.com, serascience.com), and we anticipate significant further commercial opportunities through the research programme outlined here. Development of metabolomic capacity and provision is not only intended to engage with other research areas but also provide a service to industry partners involved in therapeutics, healthcare and nutrition. Note that the proposal already has strong buy-in from industry partners in terms of technology development and implementation, with £4.2m contributed from instrument suppliers (in-kind contributions over the next five years of £2.5m and discounts on instruments of £1.7m).
We will also have major ACADEMIC impacts, where as stated our programme of work will inform research into disease pathogenesis and responsiveness to treatment, building particularly on local excellence in immune-mediated inflammatory diseases and blood cancers. Through our academic conferences as well as our existing national programmes (e.g. NIHR BRU, MRC-ARUK Centre, ARUK Centre, NIHR TRP) we will disseminate our findings, and will continue to engage with the other academic teams applying to the present call for CyTOF instruments to realise added value on a national scale. The establishment of the West Midlands Regional Phenome Centre will also have international impact in the field, providing a lasting infrastructure to support the growing requirements of phenomics in the clinical and population health arena in the UK.
Finally, we will also strive to influence key POLICY impacts, working with our clinical partners as well as organisations such as the West Midlands Academic Health Sciences Network and the funding bodies themselves, particularly in the fields of blood cancer trials and chronic inflammatory disease, to ensure that the discoveries and outputs of our research help to inform policy at a local, national and international level in terms of proactive approaches to patient stratification and treatment.
Organisations
- University of Birmingham (Lead Research Organisation)
- Versus Arthritis (Co-funder)
- University Hospital Bonn (Collaboration)
- Newcastle University (Collaboration)
- Thermo Fisher Scientific (United Kingdom) (Collaboration)
- Waters Corporation (Collaboration)
- Trinity College Dublin (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Rovira i Virgili University (Collaboration)
- EMBL European Bioinformatics Institute (EMBL - EBI) (Collaboration)
- Tharos Group (Collaboration)
- Northwestern University (Collaboration)
- University of Bristol (Collaboration)
Publications
Lugonja B
(2016)
Periodontitis prevalence and serum antibody reactivity to periodontal bacteria in primary Sjögren's syndrome: a pilot study.
in Journal of clinical periodontology
Oni C
(2016)
Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
in Rheumatology (Oxford, England)
Barone F
(2016)
Stromal Fibroblasts in Tertiary Lymphoid Structures: A Novel Target in Chronic Inflammation.
in Frontiers in immunology
Di Guida R
(2016)
Non-targeted UHPLC-MS metabolomic data processing methods: a comparative investigation of normalisation, missing value imputation, transformation and scaling.
in Metabolomics : Official journal of the Metabolomic Society
Beger RD
(2016)
Metabolomics enables precision medicine: "A White Paper, Community Perspective".
in Metabolomics : Official journal of the Metabolomic Society
Illendula A
(2016)
Small Molecule Inhibitor of CBFß-RUNX Binding for RUNX Transcription Factor Driven Cancers.
in EBioMedicine
Rantakari P
(2016)
Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury.
in Proceedings of the National Academy of Sciences of the United States of America
Hillen MR
(2016)
Towards standardisation of histopathological assessments of germinal centres and lymphoid structures in primary Sjögren's syndrome.
in Annals of the rheumatic diseases
Campos J
(2016)
Salivary Gland Pathology in Sjögren's Syndrome.
in Rheumatic diseases clinics of North America
Description | AASLD Guidleines for treatment of liver disease |
Geographic Reach | North America |
Policy Influence Type | Membership of a guideline committee |
Description | CRUK Programme Grant |
Amount | £1,505,202 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2017 |
End | 03/2022 |
Description | CRUK Project Grant |
Amount | £671,139 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2017 |
End | 09/2023 |
Description | CRUK/14/033 STAR-TREC: Saving the rectum by watchful waiting or TransAnal microsurgery following (chemo)Radiotherapy versus Total mesorectal excision for early Rectal Cancer |
Amount | £122,588 (GBP) |
Funding ID | 19393 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2016 |
End | 07/2019 |
Description | CRUK/17/014 PARC: A Phase I/II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) |
Amount | £176,411 (GBP) |
Funding ID | 24836 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2017 |
End | 11/2021 |
Description | Cancer Research UK / Medical Research Council Stratified Medicine Consortium |
Amount | £5,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2015 |
End | 03/2020 |
Description | Characterisation of Chromatin Landscapes of Pre-leukaemic and Leukaemic Stem Cells in Core Binding Factor AML and their Response to Epigenetic Therapy |
Amount | £241,299 (GBP) |
Funding ID | MR/P019609/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 07/2017 |
End | 08/2021 |
Description | Fellowship |
Amount | £1,004,344 (GBP) |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2016 |
End | 08/2021 |
Description | Finding therapeutic targets in FLT3-ITD AML using a systems biology approach |
Amount | £1,651,941 (GBP) |
Funding ID | MR/S021469/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2019 |
End | 02/2023 |
Description | Investigating the role of protein hydroxylation in cancer |
Amount | £1,300,633 (GBP) |
Funding ID | 24552 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2017 |
End | 09/2024 |
Description | Kennedy Trust for Rheumatology Research Programme Grant |
Amount | £7,010,630 (GBP) |
Organisation | The Kennedy Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2017 |
End | 05/2024 |
Description | MECHANISTIC INSIGHTS INTO THE DEVELOPMENTAL-STAGE SPECIFIC ACTIVITY OF A UBIQUITOUSLY EXPRESSED TRANSCRIPTION FACTOR |
Amount | £662,125 (GBP) |
Funding ID | BB/M020800/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2015 |
End | 01/2019 |
Description | MICA: Stratification in COloRectal cancer: from biology to Treatment prediction: S-CORT |
Amount | £5,079,623 (GBP) |
Funding ID | MR/M016587/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2015 |
End | 03/2021 |
Description | MRC infrastructure |
Amount | £7,200,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2015 |
End | 01/2019 |
Description | Mechanistic Insights Into Aberrant Transcriptional Programming In Acute Myeloid Leukaemia |
Amount | £1,543,859 (GBP) |
Funding ID | 15001 |
Organisation | Bloodwise |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2015 |
End | 12/2020 |
Description | Molecular stratification of rectal cancer. |
Amount | £317,899 (GBP) |
Funding ID | 102732 |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2014 |
End | 04/2017 |
Description | Molecular stratification of rectal cancer. |
Amount | £317,899 (GBP) |
Funding ID | 102732/Z/13/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2014 |
End | 04/2017 |
Description | NIHR Biomedical Research Centre |
Amount | £12,120,962 (GBP) |
Organisation | Government of Catalonia |
Department | Department of Health |
Sector | Public |
Country | Spain |
Start | 03/2017 |
End | 03/2022 |
Description | New therapeutic avenues in Sjogren's syndrome: exploring the role of PEPITEM in an orphan disease. |
Amount | £149,014 (GBP) |
Funding ID | 109642/Z/15/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2016 |
End | 11/2018 |
Description | Prevent Ductal Carcinoma in Situ Invasive Overtreatment Now - PRECISION |
Amount | £3,445,326 (GBP) |
Funding ID | 25272 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2017 |
End | 04/2024 |
Description | Research Grant |
Amount | £91,450 (GBP) |
Organisation | Ono Pharmaceutical |
Sector | Private |
Country | Japan |
Start | 03/2017 |
End | 03/2018 |
Description | Research Grant |
Amount | £281,683 (GBP) |
Organisation | GlaxoSmithKline (GSK) |
Sector | Private |
Country | Global |
Start | 09/2016 |
End | 03/2018 |
Description | STAR-TREC Phase 3: Saving the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early Rectal Cance |
Amount | £1,067,800 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 07/2027 |
Description | System-wide analysis of transcriptional and chromatin reprogramming by EVI1 and RUNX1-EVI1 oncoproteins |
Amount | £213,834 (GBP) |
Organisation | The Kay Kendall Leukaemia Fund |
Sector | Academic/University |
Country | United Kingdom |
Start | 05/2016 |
End | 11/2019 |
Description | Target validation and proof of function: blocking Tenascin-C in an acute mouse model of Sjögrens Syndrome (PI - Francesca Barone) |
Amount | £57,323 (GBP) |
Organisation | Nascient ltd |
Sector | Private |
Country | United Kingdom |
Start | 04/2017 |
End | 05/2018 |
Description | Tender to apply metabolomics in research at the Defence Science and Technology Laboratories in the UK |
Amount | £80,000 (GBP) |
Organisation | Defence Science & Technology Laboratory (DSTL) |
Sector | Public |
Country | United Kingdom |
Start | 09/2016 |
End | 09/2019 |
Description | Understanding the molecular basis and consequences of chemoradiosensitivity in rectal cancer in order to improve therapy (MOL-RSRC) |
Amount | £1,486,516 (GBP) |
Funding ID | 23923 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2017 |
End | 03/2022 |
Description | Collaboration with Amanda Drake |
Organisation | University of Edinburgh |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | 1. Sample preparation, data acquisition and data analysis of mouse blood and tissue samples. |
Collaborator Contribution | 1. Provision of mouse blood and tissue samples. |
Impact | 1. One publication is in press. |
Start Year | 2016 |
Description | Collaboration with Dr Colm Cunningham |
Organisation | Trinity College Dublin |
Country | Ireland |
Sector | Academic/University |
PI Contribution | 1. Preparation, data acquisition and data analysis for metabolic phenotyping of mouse biofluids and tissues to investigate the metabolic impact of delerium |
Collaborator Contribution | 1. Provision of mouse biofluids and tissues to investigate the metabolic impact of delerium |
Impact | This collaboration is multi-disciplinary and involves analytical chemists, bioinformaticians and clinical researchers |
Start Year | 2016 |
Description | Collaboration with Dr Georg Lietz |
Organisation | Newcastle University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | 1. Sample preparation, data acquisition and data analysis of pig urine and plasma for a pig model of hypervitamin A. |
Collaborator Contribution | 1. Provision of pig urine and plasma for a pig model of hypervitamin A. |
Impact | This is a multi-disciplinary collaboration involving analytical chemists, bioinformaticians and clinical scientists |
Start Year | 2017 |
Description | Collaboration with Dr Nicholas Timpson |
Organisation | University of Bristol |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | 1. Sample preparation, data acquisition and data analysis of human plasma |
Collaborator Contribution | 1. Provision of human plasma |
Impact | This is a multi-disciplinary collaboration between analytical chemists, bioinformaticians, epidemiologists and clinical scientists |
Start Year | 2016 |
Description | Collaboration with Dr Oscar Yanes |
Organisation | Rovira i Virgili University |
Country | Spain |
Sector | Academic/University |
PI Contribution | 1. Sample preparation, data acquisition and data analysis of human plasma samples. |
Collaborator Contribution | 1. Provision of human plasma samples. |
Impact | This is a multi-disciplinary collaboration between analytical chemists, bioinformaticians and clinicians |
Start Year | 2017 |
Description | Collaboration with Laura Torchen |
Organisation | Northwestern University |
Country | United States |
Sector | Academic/University |
PI Contribution | 1. Sample preparation, data acquisition and data analysis of human serum for the study of PCOS. |
Collaborator Contribution | 1. Provision of serum samples for metabolic phenotyping. |
Impact | This is a multi-disciplinary collaboration between analytical chemists, bioinformaticians and clinical scientists |
Start Year | 2016 |
Description | Collaboration with Tharos Ltd |
Organisation | Tharos Group |
Country | United Kingdom |
Sector | Private |
PI Contribution | 1. Two studies to analysis horse faeces to define metabolic differences between healthy horses and horses diagnosed with laminitis. 2. Sample preparation, data acquisition and data analysis of horse faeces. |
Collaborator Contribution | 1. Provision of horse faeces. |
Impact | This is a multi-disciplinary collaboration between analytical chemists, bioinformaticians and vets. |
Start Year | 2017 |
Description | Collaboration with Thermo Fisher Scientific to develop new metabolomic assays and software for metabolic phenotyping |
Organisation | Thermo Fisher Scientific |
Country | United States |
Sector | Private |
PI Contribution | 1. Development and validation and UPLC-MS assays for untargeted metabolomics. 2. Sharing of developed assays for distribution by Thermo Fisher Scientific. 3. Development of new metabolite annotation software. 4. Development of optimal approaches for the collection of MS/MS data in metabolic phenotyping. |
Collaborator Contribution | 1. Significant reduction in purchase costs of instruments (45% discount). 2. Early beta testing of new software and scientific instruments. 3. Priority engineer visits for scientific instruments. |
Impact | 1. Loan of a UPLC-MS instrument to the University of Birmingham to be applied for training courses and for assay development work. 2. This collaboration is multi-disciplinary and includes bioinformatics, analytical chemistry and clinical research. |
Start Year | 2013 |
Description | Collaboration with Waters Ltd to apply new metabolomic assays for metabolic phenotyping |
Organisation | Waters Corporation |
Country | United States |
Sector | Private |
PI Contribution | 1. Testing and application of standardised UPLC-MS assays for large-scale metabolic phenotyping with feedback |
Collaborator Contribution | 1. Provision of standardised UPLC-MS assays for metabolic phenotyping. 2. Provision of a UPLC-MS system for training courses. |
Impact | This is a multidisciplinary collaboration involving analytical chemists, bioinformaticians and clinical researchers |
Start Year | 2015 |
Description | EMBL-EBI hosting of software developed |
Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | My research team are developing a software for metabolite annotation of liquid chromatography-mass spectrometry datasets acquired applying metabolomic approaches. The research team is currently developing the software and will test and validate the software. Additional functions are being developed outside those defined in the grant proposal including new approaches to report confidence of accurate matching to metabolites. |
Collaborator Contribution | The EMBL-EBI team will host the software as a web-based and accessed tool for the metabolomics comunity as part of the MetaboLights data repository. |
Impact | The collaboration is multi-disciplinary (analytical chemistry, metabolomics, bioinformatics) |
Start Year | 2016 |
Description | MRC stratified medicine alcoholic hepatitis |
Organisation | Imperial College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Collaborative partnership funded by MRC lead by ICL |
Collaborator Contribution | research methods and analysis |
Impact | nil so far |
Start Year | 2017 |
Description | University of Bonn |
Organisation | University Hospital Bonn |
Country | Germany |
Sector | Academic/University |
PI Contribution | Visiting research fellow Philipp Lutz awarded 24 month fellowship to work in our laboratory on the role of NK cells in liver disease |
Collaborator Contribution | Philipp has generated new data during his stay with us that will from the basis of at least one high profile publication and also a future grant application |
Impact | Publications being prepared |
Start Year | 2015 |
Description | University of Bonn |
Organisation | University Hospital Bonn |
Country | Germany |
Sector | Academic/University |
PI Contribution | Visiting research fellow Philipp Lutz awarded 24 month fellowship to work in our laboratory on the role of NK cells in liver disease |
Collaborator Contribution | Philipp has generated new data during his stay with us that will from the basis of at least one high profile publication and also a future grant application |
Impact | Publications being prepared |
Start Year | 2015 |
Description | Trustee PSC Support |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Trustee of patients support charity responsible for overseeing charity and organising meeting to share research advances |
Year(s) Of Engagement Activity | 2015,2016,2017 |
URL | http://www.pscsupport.org.uk/?gclid=CjwKEAjwqZ7GBRC1srKSv9TV_iwSJADKTjaDl5WWgqCsixq9oG84SRlUY8FyF_2U... |